I have a few questions if anyone can be of help? I do hold but...

I have a few questions if anyone can be of help? I do hold but only joined a few months ago.

How does Syntara plan to overcome the challenges of targeting a niche market, such as myelofibrosis, especially given the dominance of ruxolitinib and its efficacy for most patients?

What strategies are in place to ensure the drug's affordability and accessibility, particularly in markets with strict regulations (e.g., Australia, Canada, EU)?

What is Syntara’s strategy for pricing its niche drugs in highly regulated markets where affordability might become a barrier?